Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tina Tan

Editor-in-Chief

London, UK
Since she began covering the medtech industry in the late 1990s, Tina Tan has seen significant changes in the industry landscape: companies bulking up to become sector heavyweights, unwieldy conglomerates restructuring to get leaner, new players with game-changing technologies growing and thriving, struggling firms sadly fizzling into oblivion. She has also witnessed how the ever-evolving healthcare environment has impacted the way medical device companies operate, inciting them to develop new technologies – and services – to meet the needs of patient, physician and, of courses, the healthcare payer. As Editor, and prior to that Business Editor, of Clinica Medtech Intelligence, it is Tina’s experience and understanding of the key issues affecting medical device companies that has enabled her to maintain the high quality, business-critical content of Clinica for which the product is recognized globally. Tina has also dabbled in other sectors outside of medtech, having written for an eyewear fashion and an alternative health publication. But as attractive as it was to get cost-price Armani frames and free samples of organic root vegetables, Tina found herself being drawn back to the excitement of the medtech sector. Like many of her long-time colleagues covering this beat, she still marvels at the incredible gizmos and gadgets that are coming out from the industry, especially from the start-ups, and the genius creativity behind these potentially life-saving technologies.  
Advertisement
Set Alert for Articles By Tina Tan

Latest From Tina Tan

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Ophthalmology Recalls

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Companies Commercial

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

M & A Commercial

Device Week, Aug. 29, 2018 – Medtronic’s Uplifting Figures And Data

The medtech industry’s No. 1 player, Medtronic, is the focus of this edition of Device Week, as the firm hit the headlines with some impressive first fiscal quarter results and positive data from a trial of its Synchromed II drug infusion pump. Medtech Insight’s Reed Miller and Tina Tan chat about what helped to boost the company’s top- and bottom-lines and delve deeper into the SISTERS trial for Synchromed and the impact these results will have on the company’s pain management business.

Device Week Sales & Earnings

Is Dexcom Piecing Together An Artificial Pancreas Puzzle With TypeZero?

The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?

Diabetic Care Commercial

Medtronic's Eyes Are Still Peeled For M&A, But Organic Growth Is The Primary Goal

Medtronic may not have hit the headlines with any M&A deals this year so far, but the medtech giant has turned in an impressive set of first-fiscal quarter results driven by strong product sales. Organic growth, according to CEO Omar Ishrak, is currently the company's main goal, but it won't dismiss any tuck-in acquisitions that complement this organic growth and the firm will act promptly when the right opportunity comes knocking.

Sales & Earnings Companies
See All
Advertisement
UsernamePublicRestriction

Register